SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE), a leading provider of novel, rapid diagnostics that improve
diagnosis of critical diseases, today announced that, in accordance with
NASDAQ Marketplace Rule 4350, 44 non-officer employees were granted inducement
stock options covering an aggregate of 62,975 shares of common stock. These
options were granted pursuant to NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv)
with the following terms: each option has been classified as a non-qualified
stock option, has an exercise price equal to the fair market value on the
grant date, has a ten-year term, and vests in 16 equal quarterly installments
over four years (on each quarterly anniversary of the applicable vesting
commencement date).
About Biosite
A leader in the drive to advance diagnosis, Biosite Incorporated is a
research-based company dedicated to the discovery and development of novel
protein-based diagnostic tests that improve a physician's ability to diagnose
debilitating and life-threatening diseases. Biosite's Triage(R) rapid
diagnostics are used in approximately 50 percent of U.S. hospitals and in over
50 international markets for toxicology screening and diagnosis of infectious
and cardiovascular disease. Information on Biosite can be found at
http://www.biosite.com
Biosite(R) Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, Vice President, Corporate &
Investor Relations of Biosite Incorporated, +1-858-455-4808, ext.
3187, npadilla@biosite.com
|
